EUVIMEDEUVIMED entdecken
Systematische Übersicht

Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts’ Opinion and Systematic Review from the Literature

Maxime Navarro, Aude Allemang-Trivalle, Sophie Leducq, Annie-Pierre Jonville-Bera, Anaïs Maurier, Tarik Zejli, Afi-Emiliène Edée, Emilie Harchaoui, Bruno Giraudeau, Annabel Maruani

Dermatology · 2023

DOI: 10.1159/000533675 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Dermatology, 2023. Verfasst von Maxime Navarro und 9 weiteren Autor:innen. Beteiligte Einrichtung: CHRU Tours, Department of Dermatology, Unit of Pediatric dermatology, Tours, France. Hauptthemen laut MEDLINE: Pneumocystis, Pneumocystis carinii, Pneumonia, Pneumocystis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vascular anomalies (VAs) are increasingly being treated with PI3K/AKT/mTOR pathway inhibitors. These drugs have immunosuppressive properties and thus theoretically overexpose patients to opportunistic infections, especially Pneumocystis jirovecii pneumonia (PJP). PJP prophylaxis use lacks consensus. We aimed to investigate the prevalence of PJP in patients receiving mTOR/PI3K/AKT inhibitors for VAs and determine any indication for pneumocystis prophylaxis in this population.

Methods

The study was conducted in 2 parts: (1) we sent a survey to a panel of international experts of VAs asking about their use of pneumocystis prophylaxis drugs and (2) we performed a systematic review of the literature of all published cases of patients receiving these drugs for VA to estimate the prevalence of PJP in this population.

Results

Answers from 68 experts were analyzed: 21 (30.9%) answered they always add PJP prophylaxis when prescribing mTOR inhibitors, 20 (29.4%) case-by-case, and 27 (39.7%) never. For the systematic review, among 3,053 reports screened, 217 were included involving 1,189 patients (1,143 received sirolimus, 38 everolimus, 4 alpelisib, 4 miransertib). Among the 1,189 cases, 2 (0.2%) PJP were reported: one under sirolimus and one under everolimus. Thus, the prevalence of PJP was estimated at 0.88 cases/1,000 patients under sirolimus (95% CI: −0.84 to 2.59) and 26.31 cases/1,000 under everolimus (95% CI: −24.58 to 77.18). Patients with PJP never received prophylaxis drugs. We found no PJP cases under alpelisib and miransertib. PJP prophylaxis was given in 218 (18.3%) cases, more frequently for children (91.3 vs. 77.2% in the non-prophylaxis group, p = 0.012), mostly trimethoprim-sulfamethoxazole (186 patients, 85.3%).

Conclusion

Our study shows that even if PJP is a rare event, it may occur in patients with VAs treated with an mTOR inhibitor. Although our results cannot allow for revising guidelines, prophylaxis with TMP-SMX might be appropriate for a subgroup of patients with risk factors for PJP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PneumocystisPneumocystis cariniiPneumonia, PneumocystisChildHumansEverolimusImmunocompromised HostMTOR InhibitorsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRetrospective StudiesTOR Serine-Threonine KinasesTrimethoprim, Sulfamethoxazole Drug CombinationThiazolesAminopyridinesImidazoles

Stichwörter der Autor:innen

AlpelisibPneumocystis infectionSirolimusVascular anomaliesmTOR inhibitors

Substanzen

EverolimusMTOR InhibitorsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesTrimethoprim, Sulfamethoxazole Drug CombinationAlpelisibThiazolesMiransertibAminopyridines

Autor:innen und Institutionen

  • CHRU Tours, Department of Dermatology, Unit of Pediatric dermatology, Tours, France.
  • Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France.
  • University of Tours, University of Nantes, INSERM 1246-SPHERE, Tours, France.
  • CHRU Tours, Department of Clinical Pharmacology, Regional Pharmacovigilance Center, Tours, France.
  • CHRU Tours, Clinical Investigation Center of Tours, INSERM 1415, Bretonneau Hospital, Tours, France.

Zitieren

APA

Navarro, M., Allemang-Trivalle, A., Leducq, S., Jonville-Bera, A. P., Maurier, A., Zejli, T., Edée, A. E., Harchaoui, E., Giraudeau, B., & Maruani, A. (2023). Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts’ Opinion and Systematic Review from the Literature. Dermatology. https://doi.org/10.1159/000533675

Vancouver

Navarro M, Allemang-Trivalle A, Leducq S, Jonville-Bera AP, Maurier A, Zejli T, et al. Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts’ Opinion and Systematic Review from the Literature. Dermatology. 2023. doi:10.1159/000533675

BibTeX
@article{Navarro2023,
  author = {Navarro, Maxime and Allemang-Trivalle, Aude and Leducq, Sophie and Jonville-Bera, Annie-Pierre and Maurier, Anaïs and Zejli, Tarik and Edée, Afi-Emiliène and Harchaoui, Emilie and Giraudeau, Bruno and Maruani, Annabel},
  title = {Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts’ Opinion and Systematic Review from the Literature},
  journal = {Dermatology},
  year = {2023},
  doi = {10.1159/000533675}
}
Kostenlos starten →